Cervicomedullary junction neoplasm

Summary

Cervicomedullary junction neoplasm (MONDO:0003108) is a cancer. A subtype of spinal cord neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervicomedullary junction neoplasm
Mondo ID	MONDO:0003108
DOID	DOID:4707
NCIT	C5423
UMLS	C1332923
MedGen	272453
Is cancer (heuristic)	yes

Also known as: cervicomedullary junction neoplasms · cervicomedullary junction tumor · cervicomedullary junction tumour · neoplasm of cervicomedullary junction · neoplasm of the cervicomedullary junction · tumor of cervicomedullary junction · tumor of the cervicomedullary junction · tumour of cervicomedullary junction · tumour of the cervicomedullary junction

Disease family

This is a subtype of spinal cord neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › spinal cord disorder › spinal cord neoplasm › cervicomedullary junction neoplasm

Related subtypes (7): spinal meningioma, neurofibroma of spinal cord, childhood spinal cord tumor, conus medullaris neoplasm, spinal cord cancer, spinal cord dermoid cyst, benign neoplasm of spinal cord

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.